Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers.
about
Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st centurySystematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activitiesMultiple system atrophy: a clinical and neuropathological perspectiveExploring the accessible conformations of N-terminal acetylated α-synucleinWrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulatorsAlpha-synuclein biology in Lewy body diseasesCerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation.Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease.Identification of glutathione S-transferase pi as a protein involved in Parkinson disease progression.Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues.In vivo imaging of alpha-synuclein in mouse cortex demonstrates stable expression and differential subcellular compartment mobility.The chaperone-like activity of α-synuclein attenuates aggregation of its alternatively spliced isoform, 112-synuclein in vitro: plausible cross-talk between isoforms in protein aggregation.Modelling the role of UCH-L1 on protein aggregation in age-related neurodegeneration.Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophyUsing 'omics' to define pathogenesis and biomarkers of Parkinson's disease.Phosphorylation regulates proteasomal-mediated degradation and solubility of TAR DNA binding protein-43 C-terminal fragmentsEffect of spermidine on misfolding and interactions of alpha-synucleinAnalysis of alpha-synuclein in malignant melanoma - development of a SRM quantification assayThe effect of SNCA 3' region on the levels of SNCA-112 splicing variant.Dopamine-mediated oxidation of methionine 127 in α-synuclein causes cytotoxicity and oligomerization of α-synuclein.Heat-mediated enrichment of α-synuclein from cells and tissue for assessing post-translational modifications.Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders.Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in MouseNeuronal to oligodendroglial α-synuclein redistribution in a double transgenic model of multiple system atrophy.Multiomic analysis of mice epilepsy models suggest that miR-21a expression modulates mRNA and protein levels related to seizure deterioration.Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression.Splicing: is there an alternative contribution to Parkinson's disease?Possible alterations in β-Synuclein, the non-amyloidogenic homologue of α-Synuclein, during progression of sporadic α-synucleinopathiesAutosomal dominant Parkinson's disease and the route to new therapies.The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.Up-regulation of SNCA gene expression: implications to synucleinopathiesPhysiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive elementImmunological features of alpha-synuclein in Parkinson's disease.Molecular pathology of Lewy body diseases.Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model.Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation.α-Synuclein and dopamine at the crossroads of Parkinson's diseaseA BACwards glance at neurodegeneration: molecular insights into disease from LRRK2, SNCA and MAPT BAC-transgenic mice.Genetic variability in SNCA and Parkinson's disease.
P2860
Q24630927-83D65CD8-6DA2-4A2F-8326-8C0BFE00C82CQ26269871-9B685BB0-1110-414E-A70D-156D82950750Q26829838-84A78799-4ACE-4074-B02D-188D6169E5A8Q26852660-C817AFB6-FD5B-4106-A45B-3FEBD7752AC4Q27000495-984F8116-A562-4A08-A7AC-2B1697B7884AQ27003541-8430B191-86D7-478C-89C2-EED9252D9460Q27311994-5947D3F5-6CD3-4B99-8D69-15907B69ABB7Q33323265-311118F2-7803-492B-A531-73EECCDE9890Q33460911-8BA594CA-3A42-4E77-A5FC-EE6C0606329DQ33510936-207D0FD8-09FF-4861-9BF7-109E3560E5A8Q33582289-EA375388-C6A8-4528-8AA3-6E93FBE8074CQ33707184-8E086BF4-155F-4073-9A36-5FE7CEEB58B5Q33719548-20132EE8-EA53-4990-A537-22DCCEAF8275Q33914242-752AAE38-4BAF-45B5-8E41-89B604C4831FQ34032608-255A9EC7-9E64-4037-B82D-9D200133443DQ34137537-1527F3FD-84F3-4623-BBE1-3F5AAFAC8EDBQ34291522-9A8CB690-A8C4-43B0-9004-A68B3359AA12Q34379982-0907FFC3-B9D6-4195-8FFF-78636747DED9Q34538444-90D6E32A-8584-48FB-9229-63C60BDB0164Q34606278-C0276CC8-3446-4399-A303-3A19369BE0C4Q34638333-BEE567A2-48E7-4459-B08D-5216B58FFF17Q34648491-8E1125D3-273D-4731-8A91-D22829535C2CQ35597118-E8CDD2DD-ED49-4FCD-8B40-930566F54A62Q35675406-8D3C9E64-99E1-4159-BE24-C129CF8E3988Q35786733-0CAD2FF1-38A1-4981-B885-C519A9C2BE4BQ35874273-8DF82C03-1459-4F60-B544-840BF5A6AACFQ35924447-5335872F-B4FA-4027-ADB7-F5CBE6B075DBQ36069844-BFC3C9B8-1E1E-4D70-8E49-2593ECF4D804Q36321837-A1B76E33-E0DA-4C38-A271-373CBFEB9E7FQ36847250-A749C47C-7C53-462C-9617-C8FAADD898E2Q37003482-E64CB548-A84C-4A15-B060-DFF95C2E97A2Q37004246-C007F8B0-FB30-4032-A10B-ECDA8BF28511Q37166339-1FCE8C28-A8D9-403D-93EB-D68E1ADCDD6DQ37232067-DCBB97A2-0319-4A94-B55B-68FBEA7C5786Q37462203-2D87451F-8CA9-4BC7-A929-2A5967D19D04Q37472054-FB1668B7-358B-4303-A9B8-B7FD216EE6B2Q37587111-B00728A5-CEAE-48C1-8A02-628CC341A526Q37801701-FC6B9FE5-72DE-452A-98C5-72D041E15438Q37905119-90139EE2-7925-4C3C-A0A5-19A4B092A9EAQ37907930-B95854D6-0D16-4BCE-8B10-4C626863C0E0
P2860
Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Alpha-synuclein structure, pos ...... cing as aggregation enhancers.
@ast
Alpha-synuclein structure, pos ...... cing as aggregation enhancers.
@en
Alpha-synuclein structure, pos ...... cing as aggregation enhancers.
@nl
type
label
Alpha-synuclein structure, pos ...... cing as aggregation enhancers.
@ast
Alpha-synuclein structure, pos ...... cing as aggregation enhancers.
@en
Alpha-synuclein structure, pos ...... cing as aggregation enhancers.
@nl
prefLabel
Alpha-synuclein structure, pos ...... cing as aggregation enhancers.
@ast
Alpha-synuclein structure, pos ...... cing as aggregation enhancers.
@en
Alpha-synuclein structure, pos ...... cing as aggregation enhancers.
@nl
P2860
P1476
Alpha-synuclein structure, pos ...... cing as aggregation enhancers.
@en
P2093
Katrin Beyer
P2860
P2888
P304
P356
10.1007/S00401-006-0104-6
P577
2006-07-15T00:00:00Z